STOCK TITAN

[6-K] Haleon plc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Haleon plc announced the purchase of 1,996,340 ordinary shares under the second tranche of its buyback programme. The trades executed on the London Stock Exchange on 29 September 2025 at an average price of £330.3042 per share. The company intends to hold the purchased shares as treasury shares.

After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are treasury shares, leaving 8,909,452,865 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company's investor website.

Haleon plc ha annunciato l'acquisto di 1.996.340 azioni ordinarie nell'ambito della seconda tranche del suo programma di buyback. Le operazioni sono state eseguite sulla London Stock Exchange il 29 settembre 2025 a un prezzo medio di £330.3042 per azione. La società intende detenere le azioni acquistate come azioni in tesoreria.

Dopo il regolamento, il capitale sociale registrato ammonta a 8.952.353.648 azioni ordinarie da £0,01 ciascuna, delle quali 42.900.783 sono azioni in tesoreria, lasciando 8.909.452.865 azioni ordinarie aventi diritto di voto. Una ripartizione completa delle singole operazioni è disponibile al link RNS fornito e sul sito investitori dell'azienda.

Haleon plc anunció la compra de 1.996.340 acciones ordinarias dentro de la segunda tranche de su programa de recompra. Las operaciones se llevaron a cabo en la London Stock Exchange el 29 de septiembre de 2025 a un precio medio de £330.3042 por acción. La compañía tiene la intención de mantener las acciones adquiridas como acciones en tesorería.

Tras el ajuste, el capital social registrado es de 8.952.353.648 acciones ordinarias de £0,01 cada una, de las cuales 42.900.783 son acciones en tesorería, quedando 8.909.452.865 acciones ordinarias con derecho a voto. Un desglose completo de las operaciones individuales está disponible en el enlace RNS proporcionado y en el sitio de inversores de la empresa.

Haleon plc가 매입 프로그램의 두 번째 트랜치 하에 1,996,340 보통주를 매입했다고 발표했습니다. 런던 증권거래소에서 2025년 9월 29일에 평균가 £330.3042로 체결되었습니다. 회사는 매입한 주식을 금고주식로 보유할 예정입니다.

결제 후 등록 자본은 8,952,353,648주의 의결권 있는 보통주로, 각 주당 £0.01이며 그 중 42,900,783주가 금고주식이며, 의결권 있는 보통주는 8,909,452,865주로 남습니다. 개별 거래에 대한 전체 내역은 제공된 RNS 링크와 회사의 투자자 웹사이트에서 확인할 수 있습니다.

Haleon plc a annoncé l'achat de 1 996 340 actions ordinaires dans le cadre de la deuxième tranche de son programme de rachat. Les transactions ont été exécutées à la London Stock Exchange le 29 septembre 2025 à un prix moyen de £330.3042 par action. La société a l'intention de détenir les actions achetées en tant que actions propres.

Après la liquidation, le capital social enregistré est de 8 952 353 648 actions ordinaires de £0,01 chacune, dont 42 900 783 sont des actions propres, laissant 8 909 452 865 actions ordinaires ayant droit de vote. Une répartition complète des transactions individuelles est disponible dans le lien RNS fourni et sur le site investisseurs de l'entreprise.

Haleon plc hat den Kauf von 1.996.340 Stammaktien im Rahmen der zweiten Tranche seines Rückkaufprogramms angekündigt. Die Trades wurden an der Londoner Börse am 29. September 2025 zu einem Durchschnittspreis von £330.3042 pro Aktie ausgeführt. Das Unternehmen beabsichtigt, die erworbenen Aktien als Eigenaktien zu halten.

Nach Abwicklung beträgt das eingetragene Grundkapital 8.952.353.648 Stammaktien zu je £0,01, von denen 42.900.783 als Eigenaktien gehalten werden, wodurch 8.909.452.865 stimmberechtigte Stammaktien verbleiben. Eine vollständige Aufschlüsselung der einzelnen Trades finden Sie unter dem bereitgestellten RNS-Link und auf der Investorenseite des Unternehmens.

Haleon plc أعلنت شراء 1,996,340 سهمًا عاديًا ضمن الجزء الثاني من برنامج إعادة شراء الأسهم. تمت الصفقات في سوق لندن للأوراق المالية في 29 سبتمبر 2025 بسعر وسط قدره £330.3042 للسهم. تعتزم الشركة الاحتفاظ بالأسهم المشتراة كـ أسهم خزينة.

بعد التسوية، يبلغ رأس المال المسجل 8,952,353,648 سهمًا عاديًا بقيمة فرنك £0.01 للسهم، من بينها 42,900,783 سهمًا خزينة، وتبقى 8,909,452,865 سهمًا عاديًا صوتيًا. يمكن العثور على تفصيل كامل لكل صفقة فردية في رابط RNS المقدم وعلى موقع الشركة للمستثمرين.

Haleon plc 在其回购计划的第二批中宣布购买了 1,996,340 股普通股。交易于 2025年9月29日 在伦敦证券交易所执行,平均价格为 £330.3042 每股。公司拟将所购股票作为 库藏股持有。

结算后,登记的股本为 8,952,353,648 股面值为 £0.01 的普通股,其中 42,900,783 股为库藏股,剩余 8,909,452,865 股具有表决权。各笔交易的完整明细可在提供的 RNS 链接及公司投资者网站查看。

Positive
  • Transparent disclosure of the trade date, number of shares purchased and average price with a link to a full trade breakdown
  • Purchased shares to be held as treasury, giving the company flexibility to reissue or cancel shares in the future
Negative
  • No information provided on remaining buyback capacity or total programme size, limiting clarity on overall capital allocation
  • Announcement omits explicit cash amount spent and does not state whether shares will be cancelled, restricting assessment of net share count impact

Insights

TL;DR: A modest-in-scale buyback increases treasury holdings and reduces outstanding voting stock, affecting share count and voting base.

The purchase of 1.996 million shares held in treasury reduces the number of voting shares to 8.909 billion, which is the figure shareholders should use to assess notification thresholds under FCA rules. The disclosure follows Market Abuse Regulation requirements by providing a trade breakdown link. The announcement is procedural and compliant; it does not provide buyback programme size or timing details for further governance implications.

TL;DR: Share repurchase completed at ~£330.30 per share; treasury increase is disclosed but impact on capital allocation is not quantified.

The announced average price of £330.3042 for 1,996,340 shares quantifies cash deployment for this tranche (~£659.5 million on a straight multiply basis, calculated from figures in the disclosure). The company states intent to hold as treasury shares, which may support future flexibility for reissuance or cancellation. The release lacks context on remaining repurchase capacity or buyback timetable, limiting assessment of broader capital-return strategy.

Haleon plc ha annunciato l'acquisto di 1.996.340 azioni ordinarie nell'ambito della seconda tranche del suo programma di buyback. Le operazioni sono state eseguite sulla London Stock Exchange il 29 settembre 2025 a un prezzo medio di £330.3042 per azione. La società intende detenere le azioni acquistate come azioni in tesoreria.

Dopo il regolamento, il capitale sociale registrato ammonta a 8.952.353.648 azioni ordinarie da £0,01 ciascuna, delle quali 42.900.783 sono azioni in tesoreria, lasciando 8.909.452.865 azioni ordinarie aventi diritto di voto. Una ripartizione completa delle singole operazioni è disponibile al link RNS fornito e sul sito investitori dell'azienda.

Haleon plc anunció la compra de 1.996.340 acciones ordinarias dentro de la segunda tranche de su programa de recompra. Las operaciones se llevaron a cabo en la London Stock Exchange el 29 de septiembre de 2025 a un precio medio de £330.3042 por acción. La compañía tiene la intención de mantener las acciones adquiridas como acciones en tesorería.

Tras el ajuste, el capital social registrado es de 8.952.353.648 acciones ordinarias de £0,01 cada una, de las cuales 42.900.783 son acciones en tesorería, quedando 8.909.452.865 acciones ordinarias con derecho a voto. Un desglose completo de las operaciones individuales está disponible en el enlace RNS proporcionado y en el sitio de inversores de la empresa.

Haleon plc가 매입 프로그램의 두 번째 트랜치 하에 1,996,340 보통주를 매입했다고 발표했습니다. 런던 증권거래소에서 2025년 9월 29일에 평균가 £330.3042로 체결되었습니다. 회사는 매입한 주식을 금고주식로 보유할 예정입니다.

결제 후 등록 자본은 8,952,353,648주의 의결권 있는 보통주로, 각 주당 £0.01이며 그 중 42,900,783주가 금고주식이며, 의결권 있는 보통주는 8,909,452,865주로 남습니다. 개별 거래에 대한 전체 내역은 제공된 RNS 링크와 회사의 투자자 웹사이트에서 확인할 수 있습니다.

Haleon plc a annoncé l'achat de 1 996 340 actions ordinaires dans le cadre de la deuxième tranche de son programme de rachat. Les transactions ont été exécutées à la London Stock Exchange le 29 septembre 2025 à un prix moyen de £330.3042 par action. La société a l'intention de détenir les actions achetées en tant que actions propres.

Après la liquidation, le capital social enregistré est de 8 952 353 648 actions ordinaires de £0,01 chacune, dont 42 900 783 sont des actions propres, laissant 8 909 452 865 actions ordinaires ayant droit de vote. Une répartition complète des transactions individuelles est disponible dans le lien RNS fourni et sur le site investisseurs de l'entreprise.

Haleon plc hat den Kauf von 1.996.340 Stammaktien im Rahmen der zweiten Tranche seines Rückkaufprogramms angekündigt. Die Trades wurden an der Londoner Börse am 29. September 2025 zu einem Durchschnittspreis von £330.3042 pro Aktie ausgeführt. Das Unternehmen beabsichtigt, die erworbenen Aktien als Eigenaktien zu halten.

Nach Abwicklung beträgt das eingetragene Grundkapital 8.952.353.648 Stammaktien zu je £0,01, von denen 42.900.783 als Eigenaktien gehalten werden, wodurch 8.909.452.865 stimmberechtigte Stammaktien verbleiben. Eine vollständige Aufschlüsselung der einzelnen Trades finden Sie unter dem bereitgestellten RNS-Link und auf der Investorenseite des Unternehmens.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F ☐           
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
30 September 2025 - “Transaction in Own Shares”
 
 
 
 
99.1
 
 
Haleon plc: Transaction in own shares
 
30 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,996,340 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Date of purchase:
29 September 2025
29 September 2025
29 September 2025
Number of Shares purchased:
1,996,340
-
-
Highest price paid per Share (p):
331.6000
-
-
Lowest price paid per Share (p):
328.7000
-
-
Volume weighted average price paid per Share (p):
330.3042
-
-
 
The Company intends to hold the purchased shares as treasury shares.
 
Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,909,452,865 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/2957B_1-2025-9-29.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: September 30, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

FAQ

How many shares did Haleon (HLN) buy back on 29 September 2025?

1,996,340 ordinary shares were purchased on 29 September 2025.

At what price did Haleon (HLN) execute the share purchases?

Average price £330.3042 per share (individual trade breakdown available at the RNS link).

Will the repurchased Haleon shares have voting rights?

No; the company intends to hold the purchased shares as treasury shares, so they are not included in the voting total.

What is Haleon's (HLN) number of voting shares after this transaction?

8,909,452,865 ordinary shares with voting rights following settlement.

Where can I find the full breakdown of Haleon's trades?

Full trade breakdown is available at the RNS link provided in the announcement and on www.haleon.com/investors.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

40.13B
4.47B
0.02%
12.85%
0.36%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge